01Biomarin Pharmaceutical reported Q3 earnings of $0.23 per share, beating consensus estimates of $-0.15 by $0.38, a 253% surprise.
02The company generated $1.0 billion in quarterly revenue, matching analyst estimates.
03Stock trades at $55.66 with a $10.2 billion market capitalization.
04Recent earnings history shows mixed performance: Q2 beat by 30.4%, Q1 missed by 14.6%, and Q4 beat by 27.8%.
Earnings Results
Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings results on November 02, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $0.23, beating the consensus estimate of $-0.15 by $0.38 per share. Revenue came in at $1.0B, beating the estimate of $1.0B.
Company Overview
Biomarin Pharmaceutical's stock moved following the earnings release. The stock currently trades at $55.66 with a market capitalization of $10.2B.
Biomarin Pharmaceutical's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
The 253% beat relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Biomarin Pharmaceutical should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.